How is Insmed (INSM) doing?

Insmed is a company in the biotechnology industry, based in Bridgewater, NJ, worth $21.8B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.

Updated Oct 9, 2026

P3 score

Middling

Insmed shares are down 38% over the past year, 46 points behind the S&P 500. Its type is Wallflower. Among large US stocks and funds it ranks in the 5th percentile on market beat, the 87th on staying power and the 100th on business growth. It appears on 9 of our dashboards, including 2nd on “Which companies are growing fastest?” and 2nd on “Who is outgrowing its rivals?”.

$100.60−38% in a yearWorth $21.8B

Compare with VRTX · ALNY · BMRN · RARE · SRPT · UTHR

Financials, earnings and news on Stox ›

Past year

The past year

Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.

INSM against the S&P 500, past year

$100 a year ago. Insmed −38%, the S&P 500 +16%.

INSMS&P 500

What kind of stock is it?

Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.

Wallflower

LaggingSteadyGrowingSold

A growing business and a steady rank, but the shares lag and sellers lead. Overlooked.

NovDecJanFebMarAprMayJunJulAugSepNow

Wallflower since Sep; Bellwether before that.

Also Wallflower (62 in all): STE · RARE · SW · STAG · MA · OMF

EmbracedToppingAccumulatingRejectedStable rankBellwetherDistribution TopCoiled SpringWallflowerHolding rankFaith TradeRolling OverBottom FishedSleepy StapleUnsteady rankHot HandChurning WinnerTurning UpShow-Me GrowerBouncy rankSpeculative PopExhausted RallyFalling KnifeBroken Year

How is it doing against its group?

Its group is Health care, 86 large US stocks and funds whose prices tend to move together. Tools, biotech and large-cap pharma — defensive growth.

INSM, past year−38%81 of 86 in the group

Rest of the group+21%equal-weighted

S&P 500+16%past year

Insmed is −38% over the past year, against +21% for the rest of the group and +16% for the S&P 500. It ranks 81st of 86 in Health care.

INSMRest of the group

Best in the groupRVMD Revolution Medicines+297%ILMN Illumina+184%NTRA Natera+133%

Worst in the groupPODD Insulet−57%BSX Boston Scientific−56%RARE Ultragenyx−50%

Its closest rivalsVRTX Vertex Pharmaceuticals+21%ALNY Alnylam Pharmaceuticals−48%BMRN BioMarin Pharmaceutical0%RARE Ultragenyx−50%SRPT Sarepta Therapeutics−24%

Health care on Stox ›

How much does it move?

Its typical daily move, against its own past year, the market and other large stocks. Swings describe risk, not direction.

About usual Insmed typically moves 5.0% in a day, about usual for it, and it swings more than 82% of large US stocks.

Typical day5.0%about $5.08 a share

Its usual4.4%about usual, 1.2× its year’s average

Against the S&P 5003.9×the index’s typical day is 1.1%

Unusual day±10.1%twice its typical day

Deepest fall, past year−57%now 52% below its high

In the S&P’s down weeks138%of the index’s fall, three years; beta 0.9

Typical daily move (ATR)Its year’s average 4.37%

INSM on our dashboards

Every question where Insmed appears, in the order of the home page, with its reading and place in that table. Select a question to open it with INSM highlighted. Select a column to sort.

Question	Reading	Place	Details
What moved this week? What’s leading	87Unusual	38 of 60	This week −9.5% · × normal week 0.9× · 1M −21%
What are this year’s biggest winners and losers? What’s leading	3Bottom	47 of 60	This year −42% · vs S&P −56 pts · Past month −21%
How much do stocks move on earnings? Earnings	96Big mover	14 of 60	Reports 2026-10-29 · Typical move 11.7% · Largest 32%
Which stocks keep losing? Leading stocks	9432 of 52 wks	30 of 60	vs S&P, 1Y −53 pts
Which companies are growing fastest? Business quality	100Fast	2 of 60	Revenue, 1Y +186% · Change +165 pts
Who is outgrowing its rivals? Business quality	100Outgrowing	2 of 60	Revenue, 1Y +186% · Rivals +11% · Lead +175 pts
Which companies invest the most in research? Business quality	99Heavy	2 of 60	R&D / revenue 75.7% · R&D a year $860.8M · R&D, 1Y +30%
Which companies pay the most in stock? Dividends and buybacks	96Heavy	15 of 60	% of revenue 10.4% · A year $118.4M
Where is trading volume surging? Who’s buying and selling	94Heavy	32 of 60	vs normal 1.4x · Traded a day $405.8M · 5D −9.5%

Go deeper on Stox

INSM’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.

Open INSM on Stox ›All 16 types on Atlas ›Its group on Stox ›

How to read this page

How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.

Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.

Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.

Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.

For financial statements, earnings and news, see INSM’s full profile on Stox.

This page is information, not investment advice. About our data and methods ›

Full profile on Stox ›Health care stocks ›VRTX · Vertex Pharmaceuticals ›ALNY · Alnylam Pharmaceuticals ›BMRN · BioMarin Pharmaceutical ›RARE · Ultragenyx ›